Skip to main content
Free research Free research Free target review with research home and workspace preview
Quick search ChEMBL 36
Loading Target Snapshot...
Querying ChEMBL database. This may take a few seconds.
Target Snapshot

CHEMBL2364162 Target Snapshot

Tumor necrosis factor ligand superfamily member 11 · SINGLE PROTEIN · Homo sapiens

Back to Search Search this target Browse approvals Evidence Card
60Compounds
25Assays
0Approved Drugs
66.0Activities
Free Research Context

Research home keeps recent targets

This target will appear in recent viewed items on this browser. Use the demo workspace to preview watch rules and decision queues.

Research home Demo workspace
Navigation

Switch target

Move to another high-traffic target or paste a specific ChEMBL target ID.

Broader Open DB context

Frame the target before identity details

Structured disease, protein, and project context should read before the lower-level identity rail.

As of 2026-09-14

Tumor necrosis factor ligand superfamily member 11 shows approved-linked disease relevance led by bone disease. 5 more disease programs remain visible in the same review block. 1 linked drug keeps the current disease frame grounded. Protein identity stays anchored to UniProt O14788. Start with bone disease, then reuse UniProt O14788 as the stable protein anchor across project notes and exports.

Review focus
Review-ready target frame

Start with bone disease, then reuse UniProt O14788 as the stable protein anchor across project notes and exports.

ChEMBL component mapping + Open Targets-ready proxy + ChEMBL 36 via Core Engine 2026-09-14 1 linked drug
Open source guide
Disease program
bone disease

Tumor necrosis factor ligand superfamily member 11 shows approved-linked disease relevance led by bone disease. 5 more disease programs remain visible in the same review block. 1 linked drug remains visible in the same block.

Start review with bone disease because it currently carries approved-linked support. Linked drugs include DENOSUMAB. This disease block keeps the Open Targets-ready contract explicit while current evidence comes from ChEMBL mechanism and indication mappings.

Disease source · ChEMBL drug mechanism + indication proxy
Approved-linked Open Targets-ready proxy 1 linked drug
Open disease block
Identity Layer

Cross-source identity

Keep the review anchor, source IDs, and context contract aligned before reusing this target elsewhere.

This review treats Tumor necrosis factor ligand superfamily member 11 as ChEMBL target CHEMBL2364162, mapped to UniProt O14788. Disease framing currently uses the Open Targets-ready proxy contract.

Review anchor
Tumor necrosis factor ligand superfamily member 11
SINGLE PROTEIN · Homo sapiens
As of 2026-09-14
ChEMBL target ID
CHEMBL2364162
Primary anchor for compounds, assays, approvals, and exports
ChEMBL 36 via Core Engine As of 2026-09-14
www.ebi.ac.uk
UniProt accession
O14788
Tumor necrosis factor ligand superfamily member 11
UniProt accession via ChEMBL component mapping As of 2026-09-14
www.uniprot.org
Disease evidence contract
Open Targets-ready proxy
ChEMBL drug mechanism + indication proxy
ChEMBL drug mechanism + indication proxy As of 2026-09-14
www.ebi.ac.uk

Reuse the same identifiers in notes, watch rules, exports, and review packs so provenance stays stable across surfaces.

Source Guidance

Start with the right source

Choose the first block or source based on the question you are trying to answer.

Need stable target naming and protein identity?
UniProt Target Context
UniProt accession via ChEMBL component mapping

Start here when your first question is whether Tumor necrosis factor ligand superfamily member 11 is the right protein anchor across sources, using UniProt O14788 as the stable mapping.

Jump to Protein Context
Need disease fit before discussing compounds?
Disease Relevance & Evidence Level
ChEMBL drug mechanism + indication proxy

Use this block first when you need to confirm why bone disease is currently framed as approved-linked support. It currently carries 1 linked drug in the same disease frame.

Jump to Disease Context
Need a meeting-ready explanation of why this target matters?
Evidence Card
Review-ready rationale with source-aware context

Open the one-page evidence card when you want the rationale, activity base, and attribution together.

Open Review-ready Card
Overview

Basic Information

Verify identity, organism, and the fastest next research jumps from the same page.

Preferred NameTumor necrosis factor ligand superfamily member 11
Target TypeSINGLE PROTEIN
OrganismHomo sapiens
UniProtO14788
ChEMBL ↗ UniProt ↗ NCBI Protein ↗

Next Actions

SearchRun a focused querySearch the database using this target name as the starting context. ApprovalsCheck approved moleculesSee which approved drugs connect back to this target and its surrounding signal space. FeedScan papers & updatesStay in the project thread while checking recent papers and platform updates.
UniProt Context

UniProt Target Context

Reviewable protein naming and mapping context for this target snapshot.

Protein LabelTumor necrosis factor ligand superfamily member 11
UniProt AccessionO14788
Component TypeProtein
Sequence Length317 aa

Tumor necrosis factor ligand superfamily member 11

Source · UniProt accession via ChEMBL component mapping
UniProt Context ↗
Review Cue

How to read this target

Review this target as Tumor necrosis factor ligand superfamily member 11, mapped to UniProt O14788. Sequence length is 317 aa.

Mapped IDO14788
Review nameTumor necrosis factor ligand superfamily member 11
OrganismHomo sapiens
Disease Relevance

Disease Relevance & Evidence Level

Open Targets-ready disease context using the current target-indication evidence contract.

Approved-linked Open Targets-ready proxy

Tumor necrosis factor ligand superfamily member 11 shows approved-linked disease relevance led by bone disease. 5 more disease programs remain visible in the same review block.

Approved-linked Approved
bone disease
1 linked drug · 1 direct · 1 efficacy
Linked drugDENOSUMAB
Approved-linked Approved
bone giant cell tumor
1 linked drug · 1 direct · 1 efficacy
Linked drugDENOSUMAB
Approved-linked Approved
bone metastasis
1 linked drug · 1 direct · 1 efficacy
Linked drugDENOSUMAB
Approved-linked Approved
bone neoplasm
1 linked drug · 1 direct · 1 efficacy
Linked drugDENOSUMAB
Approved-linked Approved
bone resorption disease
1 linked drug · 1 direct · 1 efficacy
Linked drugDENOSUMAB
Approved-linked Approved
breast cancer
1 linked drug · 1 direct · 1 efficacy
Linked drugDENOSUMAB
Source · ChEMBL drug mechanism + indication proxy
ChEMBL target record ↗
Review Cue

How to read disease relevance

Start review with bone disease because it currently carries approved-linked support. Linked drugs include DENOSUMAB. This disease block keeps the Open Targets-ready contract explicit while current evidence comes from ChEMBL mechanism and indication mappings.

Lead diseasebone disease
Strongest levelApproved-linked
Block modeOpen Targets-ready proxy
Assay Mix

Activity Type Distribution

IC5012.0
KD54.0
Lead Set

Top Inhibitors (by pChEMBL)

ChEMBL IDpChEMBLTypeValue (nM)Phase
CHEMBL4457006 6.21 Kd 614.0 Preclinical
CHEMBL255489 6.0 IC50 1000.0 Preclinical
CHEMBL4760595 5.85 IC50 1400.0 Preclinical
CHEMBL3742191 5.73 IC50 1880.0 Preclinical
CHEMBL4797434 5.72 IC50 1900.0 Preclinical
CHEMBL4750116 5.7 IC50 2000.0 Preclinical
CHEMBL3742191 5.66 Kd 2180.0 Preclinical
CHEMBL4756975 5.6 IC50 2500.0 Preclinical
CHEMBL4560856 5.57 Kd 2700.0 Preclinical
CHEMBL4745590 5.57 IC50 2700.0 Preclinical
Distribution

pChEMBL Value Distribution

20
5.0
12
5.5
2
6.0
0
6.5
0
7.0
0
7.5
0
8.0
0
8.5
0
9.0
0
9.5
pChEMBL
Assay Landscape

Assay Landscape

25
Total Assays
48
Tested Compounds
1
Assay Types
Binding — 25 assays, 48 compounds
BAO Format Assays Compounds Avg pChEMBL
cell-based format 13 11 5.6
single protein format 7 11 5.2
assay format 5 26 5.1

Confidence Score Distribution

Source · ChEMBL 36 via Core Engine